Tag Archive for: Barouch


amfAR Gives $2 Million to CVVR Researchers to Study HIV Eradication

amfAR, The Foundation for AIDS Research, announced on July 21st that a CVVR research team has been awarded $2 million to pursue a range of strategies aimed at curing HIV. The team of researchers will be led by Dan Barouch, M.D., Ph.D., and will investigate the ability of combinations of antibodies to specifically kill latently infected cells in the lab, in monkeys, and then in people. The researchers will test two promising antibodies alone and together, in combination with a newly described drug that can “shock” the virus out of latently infected cells and possibly enhance the ability of the antibodies to locate the infected cells.

See full press release from amfAR here 


The Bad Side of CD4 T Cells

CVVR in the News:

Vaccine-Induced CD4 T Cells Lead to Adverse Effect in a Mouse Model of Infection” – Science Daily, Jan 15, 2015

“A study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) has found that a vaccine that elicits only CD4 T cells against a mouse model of a chronic viral infection results in an overwhelming — and lethal — inflammatory response. Reported in the January 16, 2015 issue of the journal Science, the new findings provide a cautionary tale for the development of vaccines aimed at eliciting robust CD4 T cell immunity against chronic infections, including HIV.” See full article >


New Vaccine Shows Protection in Monkeys

Dan Barouch and colleagues reported in the journal Science on July 17th that an adenovirus-based HIV vaccine demonstrated complete protection in 50% of vaccinated animals against a series of repeated, heterologous, intrarectal SIV challenges that infected all controls. Protective efficacy correlated with the functionality of Env-specific antibody responses. Comparable protection was also observed with a similar Ad/Env vaccine against repeated, heterologous, intrarectal SHIV-SF162P3 challenges. Clinical trials of these vaccine candidates are ongoing, in collaboration with Johnson and Johnson, the U.S. Military HIV Research Program, the International AIDS Vaccine Institute, and the U.S. National Institutes of Health.